New Study on AstraZeneca COVID-19 Drug Gives Glimpse of Hope
Written by Mfundo on 12 October, 2021
By: Staff Writer
A late-stage study has revealed that AstraZeneca’s experimental COVID-19 antibody drug cocktail has succeeded in reducing severe disease or death in non-hospitalised patients.
According to the study, the AZD7442 drug reduced the risk of developing severe Covid-19 or death by 50-percent in patients who had been symptomatic for seven days or less.
Executive Vice President, Biopharmaceuticals Research and Development at AstraZeneca, Mene Pangalos, says an early intervention with the antibody can give a significant reduction in progression to severe disease, with continued protection for more than six months.